Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.69 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.65 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.65 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.65 |
| ▸ | ABCB1 | P08183 | 5/20 | 0.64 |
| ▸ | HTR1A | P08908 | 2/20 | 0.64 |
| ▸ | DRD2 | P14416 | 2/20 | 0.64 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.62 |
| ▸ | MAOB | P27338 | 1/20 | 0.61 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.61 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.60 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.60 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.59 |
| ▸ | DRD4 | P21917 | 1/20 | 0.58 |
| ▸ | IDO1 | P14902 | 1/20 | 0.58 |
| ▸ | AGXT | P21549 | 1/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL723511 | 0.94 | TAAR1 (0.77) | TAAR1CHRM2CHRM1CHRM3ABCB1 | |
| SCHEMBL30080050 | 0.94 | TAAR1 (0.77) | TAAR1CHRM2CHRM1CHRM3ABCB1 | |
| SCHEMBL12630196 | 0.90 | SIGMAR1 (0.66) | TAAR1CHRM2CHRM1CHRM3ABCB1 | |
| SCHEMBL4949653 | 0.90 | TAAR1 (0.67) | TAAR1CHRM2CHRM1CHRM3ABCB1 | |
| SCHEMBL17779986 | 0.89 | BACE1 (0.62) | TAAR1CHRM2CHRM1CHRM3ABCB1 | |
| SCHEMBL1975466 | 0.88 | TAAR1 (0.69) | TAAR1CHRM2CHRM1CHRM3ABCB1 | |
| SCHEMBL9517424 | 0.87 | CHRM2 (0.70) | TAAR1CHRM2CHRM1CHRM3SIGMAR1 | |
| Anisole SCHEMBL11292922 | 0.87 | CA4 (0.70) | TAAR1ABCB1SIGMAR1MAOB | |
| SCHEMBL22858341 | 0.86 | TAAR1 (0.62) | TAAR1CHRM2CHRM1CHRM3ABCB1 | |
| SCHEMBL7336705 | 0.86 | TAAR1 (0.67) | TAAR1CHRM2CHRM1CHRM3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104761470-B | The preparation method of (R, S)-2-[[5-(9-fluorenylmethyloxycarbonyl amino) dibenzo [a, d] cycloheptane-2-base] oxygen] acetic acid | 吉尔生化（上海）有限公司 | 2016-08-24 | — | — | CN | claimed |
| WO-2022194128-A1 | DIPHENYL ALKANE COMPOUND AND PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 中国医学科学院药物研究所 | 2022-09-22 | — | — | WO | disclosed |
| EP-3618819-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | Exciva GmbH (DE) | 2020-03-11 | — | — | EP | disclosed |
| WO-2018204713-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | EXCIVA UG (HAFTUNGSBESCHRÄNKT) (DE) | 2018-11-08 | — | — | WO | disclosed |
| WO-2017161145-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE AND/OR EPX | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-21 | — | — | WO | disclosed |
| WO-2017023821-A1 | BOTANICAL IDENTIFICATION METHOD AND SYSTEM | SCIENTIFIC HOLDINGS, LLC (US) | 2017-02-09 | — | — | WO | disclosed |
| US-20120321533-A1 | CATALYST | ALMQVIST FREDRIK (SE) | 2012-12-20 | — | — | US | disclosed |
| US-20100119424-A1 | CATALYST | ALMQUEST AB (SE) | 2010-05-13 | — | — | US | disclosed |
| WO-2009111337-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | IRM LLC (BM) | 2009-09-11 | — | — | WO | disclosed |
| US-20090012308-A1 | PROCESS FOR THE MANUFACTURE OF BENZYLSULFONYLARENES | WYETH (US) | 2009-01-08 | — | — | US | disclosed |
| WO-2008138938-A2 | PROCESS FOR THE PRODUCTION OF PALLADIUM SUPPORTED CATALYSTS FOR CATALYZING HECK, SUZUKI-MIYAURA SONOGASHIRA COUPLING AND BUCHWALD-HARTWIG REACTIONS | NORDIC CHEMQUEST AB (SE) | 2008-11-20 | — | — | WO | disclosed |
| US-6030975-A | ANTAGONIST OF ENDOTHELINS, I.E. INHIBITION OF BINDING WITH RECEPTOR; ANTITUMOR AND -CARCINOGENIC AGENTS; SIDE EFFECT REDUCTION | BASF AKTIENGESELLSCHAFT (DE) | 2000-02-29 | — | — | US | disclosed |
| US-5840722-A | ADMINISTERING TO INHIBIT ENDOTHELIN RECEPTORS | BASF AKTIENGESELLSCHAFT (DE) | 1998-11-24 | — | — | US | disclosed |
| US-5703017-A | HERBICIDES, PLANT GROWTH REGULATORS | BASF AKTIENGESELLSCHAFT (DE) | 1997-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012308-A1 | PROCESS FOR THE MANUFACTURE OF BENZYLSULFONYLARENES | HTR6, HTR2B, HTR3B | TAAR1 113/4885CHRM2 673/4885CHRM1 1379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.